Intermittent Vs Continuous Administration of Nerve Growth Factor to Injured Medial Septal Cholinergic Neurons in Rat Basal Forebrain

Overview

Journal Neurosci Med

Date 2018 Nov 27

PMID 30473908

Authors

Kenneth E Miller

Gregory E Frierdich

Robert H Dillard

Robert H Soriano

Dikla G Roufa

Affiliations

Soon will be listed here.

Abstract

Many medial septal neurons of the basal forebrain are dependent on nerve growth factor (NGF) from the hippocampus for survival and maintenance of a cholinergic phenotype. When deprived of their source of NGF by axotomy, medial septal neuronal cell bodies atrophy and lose their cholinergic markers. This is similar to what is observed in the basal forebrain during Alzheimer's disease (AD). In the present study, medial septal neurons were axotomized in female rats by way of a fimbria/fornix lesion. For fourteen days following axotomy, varying NGF doses (1 - 250 μg/ml) were administered to the lateral cerebral ventricle with either mini-osmotic infusion or daily injection. The responsiveness of medial septal neurons was evaluated with choline acetyltransferase immunohistochemistry. Within the mini-osmotic pumps, NGF activity diminished greatly during the first five days of implantation, but increased dramatically in the CSF after five days of infusion. The responsiveness of medial septal neurons to NGF was dose dependent and the ED for NGF injection was determined to be 14.08 μg/ml compared to 27.60 μg/ml for NGF infusion. Intermittent injections at varying intervals were evaluated with 30 μg/ml NGF over a fourteen-day time period (2, 3, 6, or 12 injections). No differences occurred in the number of choline acetyltransferase neurons from rats that received weekly injections to those that received daily injections of NGF. NGF administration has been suggested as a therapy for AD. The results of these studies continue to highlight the need for NGF stability within the delivery system and AD patient CSF, the choice of delivery system, frequency of administration, and the NGF dose for maintaining basal forebrain cholinergic neurons during AD.

References

Gage F, Armstrong D, Williams L, Varon S . Morphological response of axotomized septal neurons to nerve growth factor. J Comp Neurol. 1988; 269(1):147-55. DOI: 10.1002/cne.902690112. View

Eriksdotter Jonhagen M, Nordberg A, Amberla K, Backman L, Ebendal T, Meyerson B . Intracerebroventricular infusion of nerve growth factor in three patients with Alzheimer's disease. Dement Geriatr Cogn Disord. 1998; 9(5):246-57. DOI: 10.1159/000017069. View

Pombero A, Bueno C, Saglietti L, Rodenas M, Guimera J, Bulfone A . Pallial origin of basal forebrain cholinergic neurons in the nucleus basalis of Meynert and horizontal limb of the diagonal band nucleus. Development. 2011; 138(19):4315-26. DOI: 10.1242/dev.069534. View

Whittemore S, Friedman P, Larhammar D, Persson H, Holets V . Rat beta-nerve growth factor sequence and site of synthesis in the adult hippocampus. J Neurosci Res. 1988; 20(4):403-10. DOI: 10.1002/jnr.490200402. View

OBrien T, Svendsen C, Isacson O, Sofroniew M . Loss of true blue labelling from the medial septum following transection of the fimbria-fornix: evidence for the death of cholinergic and non-cholinergic neurons. Brain Res. 1990; 508(2):249-56. DOI: 10.1016/0006-8993(90)90403-x. View

Linke R, Frotscher M . Development of the rat septohippocampal projection: tracing with DiI and electron microscopy of identified growth cones. J Comp Neurol. 1993; 332(1):69-88. DOI: 10.1002/cne.903320106. View

Olson L, Nordberg A, von Holst H, Backman L, Ebendal T, Alafuzoff I . Nerve growth factor affects 11C-nicotine binding, blood flow, EEG, and verbal episodic memory in an Alzheimer patient (case report). J Neural Transm Park Dis Dement Sect. 1992; 4(1):79-95. DOI: 10.1007/BF02257624. View

Williams L, Inouye G, Cummins V, Pelleymounter M . Glial cell line-derived neurotrophic factor sustains axotomized basal forebrain cholinergic neurons in vivo: dose-response comparison to nerve growth factor and brain-derived neurotrophic factor. J Pharmacol Exp Ther. 1996; 277(2):1140-51. View

Gu H, Long D, Song C, Li X . Recombinant human NGF-loaded microspheres promote survival of basal forebrain cholinergic neurons and improve memory impairments of spatial learning in the rat model of Alzheimer's disease with fimbria-fornix lesion. Neurosci Lett. 2009; 453(3):204-9. DOI: 10.1016/j.neulet.2009.02.027. View

10.

Hess C, BLOZOVSKI D . [Intrahippocampal injection of NGF accelerates spontaneous alteration ontogenesis and the maturation of septohippocampal cholinergic innervation in rats]. C R Acad Sci III. 1990; 310(11):533-8. View

11.

Bandtlow C, Meyer M, Lindholm D, Spranger M, Heumann R, Thoenen H . Regional and cellular codistribution of interleukin 1 beta and nerve growth factor mRNA in the adult rat brain: possible relationship to the regulation of nerve growth factor synthesis. J Cell Biol. 1990; 111(4):1701-11. PMC: 2116238. DOI: 10.1083/jcb.111.4.1701. View

12.

Aloe L, Rocco M, Bianchi P, Manni L . Nerve growth factor: from the early discoveries to the potential clinical use. J Transl Med. 2012; 10:239. PMC: 3543237. DOI: 10.1186/1479-5876-10-239. View

13.

Koliatsos V, Applegate M, Knusel B, Junard E, Burton L, Mobley W . Recombinant human nerve growth factor prevents retrograde degeneration of axotomized basal forebrain cholinergic neurons in the rat. Exp Neurol. 1991; 112(2):161-73. DOI: 10.1016/0014-4886(91)90066-l. View

14.

Williams L, Varon S, Peterson G, Wictorin K, Fischer W, Bjorklund A . Continuous infusion of nerve growth factor prevents basal forebrain neuronal death after fimbria fornix transection. Proc Natl Acad Sci U S A. 1986; 83(23):9231-5. PMC: 387109. DOI: 10.1073/pnas.83.23.9231. View

15.

Emmett C, Aswani S, Stewart G, Fairchild D, Johnson R . Dose-response comparison of recombinant human nerve growth factor and recombinant human basic fibroblast growth factor in the fimbria fornix model of acute cholinergic degeneration. Brain Res. 1995; 673(2):199-207. DOI: 10.1016/0006-8993(94)01414-d. View

16.

Williams L, Jodelis K, Donald M . Axotomy-dependent stimulation of choline acetyltransferase activity by exogenous mouse nerve growth factor in adult rat basal forebrain. Brain Res. 1989; 498(2):243-56. DOI: 10.1016/0006-8993(89)91103-7. View

17.

Gage F, Wictorin K, Fischer W, Williams L, Varon S, Bjorklund A . Retrograde cell changes in medial septum and diagonal band following fimbria-fornix transection: quantitative temporal analysis. Neuroscience. 1986; 19(1):241-55. DOI: 10.1016/0306-4522(86)90018-7. View

18.

Kromer L . Nerve growth factor treatment after brain injury prevents neuronal death. Science. 1987; 235(4785):214-6. DOI: 10.1126/science.3798108. View

19.

Rafii M, Baumann T, Bakay R, Ostrove J, Siffert J, Fleisher A . A phase1 study of stereotactic gene delivery of AAV2-NGF for Alzheimer's disease. Alzheimers Dement. 2014; 10(5):571-81. DOI: 10.1016/j.jalz.2013.09.004. View

20.

Vahlsing H, Hagg T, Spencer M, Conner J, Manthorpe M, Varon S . Dose-dependent responses to nerve growth factor by adult rat cholinergic medial septum and neostriatum neurons. Brain Res. 1991; 552(2):320-9. DOI: 10.1016/0006-8993(91)90098-g. View